These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

127 related articles for article (PubMed ID: 2868866)

  • 1. Phencyclidine-specific Fab fragments alter phencyclidine disposition in dogs.
    Owens SM; Mayersohn M
    Drug Metab Dispos; 1986; 14(1):52-8. PubMed ID: 2868866
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Anti-phencyclidine monoclonal Fab fragments markedly alter phencyclidine pharmacokinetics in rats.
    Valentine JL; Arnold LW; Owens SM
    J Pharmacol Exp Ther; 1994 Jun; 269(3):1079-85. PubMed ID: 8014850
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Disposition of a monoclonal anti-phencyclidine Fab fragment of immunoglobulin G in rats.
    McClurkan MB; Valentine JL; Arnold L; Owens SM
    J Pharmacol Exp Ther; 1993 Sep; 266(3):1439-45. PubMed ID: 8371148
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Antiphencyclidine monoclonal antibody therapy significantly changes phencyclidine concentrations in brain and other tissues in rats.
    Valentine JL; Owens SM
    J Pharmacol Exp Ther; 1996 Aug; 278(2):717-24. PubMed ID: 8768723
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Reversal of advanced digitoxin toxicity and modification of pharmacokinetics by specific antibodies and Fab fragments.
    Ochs HR; Smith TW
    J Clin Invest; 1977 Dec; 60(6):1303-13. PubMed ID: 914999
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Colchicine-specific Fab fragments alter colchicine disposition in rabbits.
    Sabouraud AE; Urtizberea M; Cano NJ; Grandgeorge M; Rouzioux JM; Scherrmann JM
    J Pharmacol Exp Ther; 1992 Mar; 260(3):1214-9. PubMed ID: 1545388
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Modulation of phencyclidine (PCP) pharmacokinetics with PCP-specific Fab fragments.
    Owens SM; Mayersohn M
    NIDA Res Monogr; 1986; 64():112-26. PubMed ID: 3086729
    [No Abstract]   [Full Text] [Related]  

  • 8. Anti-phencyclidine monoclonal antibodies provide long-term reductions in brain phencyclidine concentrations during chronic phencyclidine administration in rats.
    Proksch JW; Gentry WB; Owens SM
    J Pharmacol Exp Ther; 2000 Mar; 292(3):831-7. PubMed ID: 10688594
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Phencyclidine (PCP) disposition kinetics in dogs as a function of dose and route of administration.
    Woodworth JR; Owens SM; Mayersohn M
    J Pharmacol Exp Ther; 1985 Sep; 234(3):654-61. PubMed ID: 4032285
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Pharmacokinetic mechanisms for obtaining high renal coelimination of phencyclidine and a monoclonal antiphencyclidine antigen-binding fragment of immunoglobulin G in the rat.
    Proksch JW; Gentry WB; Owens SM
    J Pharmacol Exp Ther; 1998 Nov; 287(2):616-24. PubMed ID: 9808688
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Disposition kinetics of the monohydroxy metabolites of phencyclidine in the dog.
    Woodworth JR; Mayersohn M; Owens SM
    J Pharmacol Exp Ther; 1986 Sep; 238(3):900-4. PubMed ID: 3746667
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Immunogenicity and kinetics of distribution and elimination of sheep digoxin-specific IgG and Fab fragments in the rabbit and baboon.
    Smith TW; Lloyd BL; Spicer N; Haber E
    Clin Exp Immunol; 1979 Jun; 36(3):384-96. PubMed ID: 114346
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Antiphencyclidine monoclonal Fab fragments reverse phencyclidine-induced behavioral effects and ataxia in rats.
    Valentine JL; Mayersohn M; Wessinger WD; Arnold LW; Owens SM
    J Pharmacol Exp Ther; 1996 Aug; 278(2):709-16. PubMed ID: 8768722
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Comparison of two and three compartment models of phencyclidine in man.
    Domino SE; Domino LE; Domino EF
    Subst Alcohol Actions Misuse; 1982; 3(4):205-11. PubMed ID: 7167862
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Pharmacokinetics and toxicity of high doses of antibody Fab fragments in rats.
    Pentel PR; Keyler DE; Gilbertson DG; Ruth G; Pond SM
    Drug Metab Dispos; 1988; 16(1):141-5. PubMed ID: 2894943
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Phencyclidine disposition in humans after small doses of radiolabeled drug.
    Cook CE; Perez-Reyes M; Jeffcoat AR; Brine DR
    Fed Proc; 1983 Jun; 42(9):2566-9. PubMed ID: 6852275
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Phencyclidine blood protein binding: influence of protein, pH and species.
    Owens SM; Mayersohn M; Woodworth JR
    J Pharmacol Exp Ther; 1983 Sep; 226(3):656-60. PubMed ID: 6887006
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Pharmacodynamics of a monoclonal antiphencyclidine Fab with broad selectivity for phencyclidine-like drugs.
    Hardin JS; Wessinger WD; Proksch JW; Owens SM
    J Pharmacol Exp Ther; 1998 Jun; 285(3):1113-22. PubMed ID: 9618414
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Long-term disposition of phencyclidine in mice.
    Martin BR
    Drug Metab Dispos; 1982; 10(2):189-93. PubMed ID: 6124408
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The pharmacokinetics of [3H]1-[1-(2-thienyl)cyclohexyl]piperidine (TCP) in Sprague-Dawley rats.
    Zorbas M; Owens SM; Plunkett LM; Bui H
    Drug Metab Dispos; 1989; 17(6):641-5. PubMed ID: 2575500
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.